Answers are grounded in this paper and cite their sources.
MicroRNAs are short non-coding RNA molecules that regulate gene expression and contribute to cancer development as oncomiRs or tumour suppressors. Their therapeutic modulation using miRNA mimics or antimiRs is promising; however, systemic instability, poor cellular uptake, endosomal entrapment, off-target effects and innate immune activation limit their clinical efficacy. Using aptamer-functionalised nanocarriers, offers a strategy to protect miRNAs, enhance tumour-selective uptake and pharmacokinetic behaviour, improve precise tumour targeting, enable stimulus-responsive release and facilitate intracellular delivery. This review provides an overview on polymeric, inorganic, lipid-based and nucleic acid-based nanocarriers functionalised with targeting aptamers, comparing therapeutic miRNAs, cancer models, delivery mechanisms, release strategies, biosafety and efficacy. Preclinical studies demonstrate enhanced tumour accumulation, apoptosis induction, inhibition of proliferation and metastasis, and reversal of multidrug resistance, while combination platforms can potentiate chemotherapy and other therapies. Nevertheless, efficient receptor targeting does not guarantee cytosolic delivery; endosomal escape remains a critical bottleneck, while aptamer stability, affinity, orientation, ligand density and protein-corona effects require optimisation. Translation is further constrained by limited long-term safety and biodistribution data, tumour heterogeneity, manufacturing complexity, scalability and regulatory barriers. Future progress requires multifunctional, multi-stimuli-responsive systems, standardised evaluation, rigorous safety assessment and AI-assisted optimisation to support more reproducible, safer and potentially personalised miRNA cancer therapies.
No takes yet. Share an insight, caveat, or question.
Gholami et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: